ACR: Biologics Prove Ineffective for Lupus

SAN FRANCISCO, Oct. 29 – Two biologics tried off-label for systemic lupus erythematosus failed to meet any endpoints in randomized trials, researchers reported here.

Neither rituximab (Rituxan) nor abatacept (Orencia) improved any primary or secondary endpoint, reported Joan T. Merrill, M.D., of the University of Oklahoma in Oklahoma City, and colleagues at the American College of Rheumatology meeting.

Read full article